Ultragenyx Pharmaceutical Balance Sheet Health
Financial Health criteria checks 4/6
Ultragenyx Pharmaceutical has a total shareholder equity of $432.4M and total debt of $889.1M, which brings its debt-to-equity ratio to 205.6%. Its total assets and total liabilities are $1.6B and $1.2B respectively.
Key information
205.6%
Debt to equity ratio
US$889.08m
Debt
| Interest coverage ratio | n/a |
| Cash | US$763.82m |
| Equity | US$432.42m |
| Total liabilities | US$1.19b |
| Total assets | US$1.62b |
Recent financial health updates
We Think Ultragenyx Pharmaceutical (NASDAQ:RARE) Has A Fair Chunk Of Debt
Sep 04
We Think Ultragenyx Pharmaceutical (NASDAQ:RARE) Has A Fair Chunk Of Debt
May 24Will Ultragenyx Pharmaceutical (NASDAQ:RARE) Spend Its Cash Wisely?
Feb 01Recent updates
We Think Ultragenyx Pharmaceutical (NASDAQ:RARE) Has A Fair Chunk Of Debt
Sep 04Ultragenyx's Strong Pipeline And Valuation Concerns: A Balanced Perspective
Aug 22There's Reason For Concern Over Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) Massive 26% Price Jump
Aug 03Shareholders Will Probably Hold Off On Increasing Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) CEO Compensation For The Time Being
Jun 12Ultragenyx: Modest Sales Growth, With Multiple Inflection Points Approaching
Jun 06We Think Ultragenyx Pharmaceutical (NASDAQ:RARE) Has A Fair Chunk Of Debt
May 24Ultragenyx Pharmaceutical Earnings: No Visible Path To Financial Success Yet
Mar 09Will Ultragenyx Pharmaceutical (NASDAQ:RARE) Spend Its Cash Wisely?
Feb 01There's No Escaping Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) Muted Revenues Despite A 28% Share Price Rise
Dec 28Is There An Opportunity With Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) 47% Undervaluation?
Sep 12An Intrinsic Calculation For Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Suggests It's 50% Undervalued
May 24Improved Revenues Required Before Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Find Their Feet
Apr 17Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Could Be 33% Below Their Intrinsic Value Estimate
Feb 18Ultragenyx upgraded to buy at Guggenheim as stock trading at discount to biotech peers
Oct 13Ultragenyx grants stock options, restricted stock units
Oct 05Ultragenyx Pharmaceuticals: Downward Trajectory Likely To Continue
Sep 02Financial Position Analysis
Short Term Liabilities: RARE's short term assets ($964.6M) exceed its short term liabilities ($272.9M).
Long Term Liabilities: RARE's short term assets ($964.6M) exceed its long term liabilities ($913.2M).
Debt to Equity History and Analysis
Debt Level: RARE's net debt to equity ratio (29%) is considered satisfactory.
Reducing Debt: RARE's debt to equity ratio has increased from 0% to 205.6% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: RARE has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if RARE has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.